Can-Fite BioPharma Ltd. (CANF) stock
CANFNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.42−0.07 (-4.70%)
Close on Nov 13, 2026Market cap $1.86MP/E –Yield –
Earnings
Can-Fite BioPharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of Can-Fite BioPharma's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
Can-Fite BioPharma has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When Can-Fite BioPharma puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases Can-Fite BioPharma filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?